Comment
Author: Admin | 2025-04-28
That the combination of buspirone and benzodiazepines can potentiate the CNS effects (e.g., increased sedation or respiratory depression) of either agent. [28501] [30414] [41551] Chlorpheniramine; Codeine: (Moderate) Concomitant use of CNS depressants, such as buspirone, can potentiate the effects of codeine, which may potentially lead to respiratory depression, CNS depression, sedation, or hypotensive responses. If concurrent use of codeine and buspirone is imperative, reduce the dose of one or both drugs. [33654] Chlorpheniramine; HYDROcodone: (Moderate) Concomitant use of hydrocodone with other central nervous system depressants, such as buspirone, can potentiate the effects of hydrocodone and may lead to additive CNS or respiratory depression. If hydrocodone is used with buspirone, the dose of one or both drugs should be reduced. [30379] Ciprofloxacin: (Moderate) Monitor for an increase in buspirone-related adverse reactions if coadministration with ciprofloxacin is necessary; the effect may be more pronounced if the patient has been titrated to a stable dose of buspirone and ciprofloxacin is added or removed from therapy. Buspirone is a sensitive CYP3A substrate and ciprofloxacin is a moderate CYP3A inhibitor. Coadministration with other moderate CYP3A inhibitors increased buspirone exposure by 3.4 to 6-fold and was accompanied by increased buspirone-related adverse reactions. [28501] [56579] Citalopram: (Moderate) Coadministration of buspirone with citalopram may increase the risk of serotonin syndrome. Buspirone has some serotonergic properties. Inform patients of the possible increased risk and monitor for the emergence of serotonin syndrome, particularly during treatment initiation and dose increases. If serotonin syndrome occurs, all serotonergic drugs should be discontinued and appropriate medical treatment should be initiated. [28269] [28501] [29520] Clarithromycin: (Moderate) Concomitant administration of clarithromycin with buspirone may result in increases in buspirone AUC; the mechanism is probably reduced buspirone metabolism via CYP3A4. A low dose of buspirone is recommended if administered with significant CYP3A4 inhibitors. Subsequent dose adjustments should be based on clinical assessment. [5231] cloBAZam: (Moderate) Concomitant administration of benzodiazepines like clobazam with CNS-depressant drugs, including buspirone, may potentiate the CNS effects (e.g., increased sedation or respiratory depression) of either agent. [28501] [30414] clomiPRAMINE: (Moderate) Coadministration of buspirone with tricyclic antidepressants (TCAs) may increase the risk of serotonin syndrome. Both types of medications have serotonergic properties. Inform patients of the possible increased risk and monitor for the emergence of serotonin syndrome, particularly during treatment initiation and dose increases. If serotonin syndrome occurs, all serotonergic drugs should be discontinued and appropriate medical treatment should be initiated. [28501] [28562] [28567] [29610] [39684] [42075] [61721] Clorazepate: (Moderate) It is common for patients to overlap anxiety treatment when switching from benzodiazepines to buspirone. Buspirone has a slow onset of action and the drug will not block the withdrawal syndrome often seen with cessation of benzodiazepine therapy in those with benzodiazepine dependence. Therefore, before starting therapy with buspirone, withdraw patients gradually from the benzodiazepine. Alternatively, conversion to buspirone therapy may require treatment overlap to allow for the downward titration of the benzodiazepine while buspirone takes effect. It should be noted that the combination of buspirone and benzodiazepines can potentiate the CNS effects (e.g.,
Add Comment